Technical Analysis for MRSN - Mersana Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.88 | -10.28% | -0.33 |
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | -10.28% | |
| Narrow Range Bar | Range Contraction | -10.28% | |
| Lower Bollinger Band Walk | Weakness | -10.28% |
| Alert | Time |
|---|---|
| Down 10% | about 15 hours ago |
| Down 1 ATR | about 15 hours ago |
| Fell Below Lower Bollinger Band | about 16 hours ago |
| Down 5% | about 17 hours ago |
| Lower Bollinger Band Support | about 17 hours ago |
Get a Trading Assistant
- Earnings date: 05/07/2024
Mersana Therapeutics, Inc. Description
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Immunology Clinical Development Monoclonal Antibodies Chemotherapy Antibody Drug Conjugate Synaffix
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.62 |
| 52 Week Low | 0.8014 |
| Average Volume | 2,323,611 |
| 200-Day Moving Average | 2.57 |
| 50-Day Moving Average | 4.41 |
| 20-Day Moving Average | 3.85 |
| 10-Day Moving Average | 3.44 |
| Average True Range | 0.31 |
| RSI (14) | 23.08 |
| ADX | 25.32 |
| +DI | 12.92 |
| -DI | 35.44 |
| Chandelier Exit (Long, 3 ATRs) | 3.87 |
| Chandelier Exit (Short, 3 ATRs) | 3.74 |
| Upper Bollinger Bands | 4.82 |
| Lower Bollinger Band | 2.87 |
| Percent B (%b) | 0.0 |
| BandWidth | 50.65 |
| MACD Line | -0.39 |
| MACD Signal Line | -0.30 |
| MACD Histogram | -0.0933 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.57 | ||||
| Resistance 3 (R3) | 3.62 | 3.44 | 3.46 | ||
| Resistance 2 (R2) | 3.44 | 3.26 | 3.42 | 3.42 | |
| Resistance 1 (R1) | 3.16 | 3.16 | 3.07 | 3.11 | 3.38 |
| Pivot Point | 2.98 | 2.98 | 2.94 | 2.96 | 2.98 |
| Support 1 (S1) | 2.70 | 2.80 | 2.61 | 2.65 | 2.38 |
| Support 2 (S2) | 2.52 | 2.70 | 2.50 | 2.34 | |
| Support 3 (S3) | 2.24 | 2.52 | 2.31 | ||
| Support 4 (S4) | 2.19 |
